Advagene Biopharma Co., Ltd. (TPEX:6709)

Taiwan · Delayed Price · Currency is TWD

24.45

+0.65 (2.73%)

Sep 15, 2026, 1:29 PM CST

Advagene Biopharma Financials Overview

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Income	-92.94	-70.92	-70.82	-93.34	-119.81	-94.43
Net Income	-91.05	-68.29	-69.42	-92.11	-118.38	-92.69
Earnings Per Share	-1.52	-1.15	-1.27	-1.83	-2.40	-1.90
EPS Growth	-	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	325.18	134.83	202.32	125.19	103.01	223.83
Total Debt	2.13	3.97	5.82	-	2.01	3.84
Net Cash (Debt)	323.05	130.87	196.5	125.19	101	220
Net Cash Growth	146.86%	-33.40%	56.96%	23.95%	-54.09%	-17.87%
Net Cash Per Share	5.38	2.20	3.60	2.48	2.05	4.51

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-87.92	-63.33	-70.65	-77.7	-109.35	-67.18
Capital Expenditures	-2.71	-2.31	-0.48	-	-0.21	-0.52
Free Cash Flow	-90.62	-65.64	-71.12	-77.7	-109.56	-67.7
Free Cash Flow Growth	-	-	-	-	-	-

Valuation

Selected indicators aren't available for this stock.